Breathe Easier App for Lung Cancer (Breathe Easier Trial)

Phase < 1

Waitlist Available

Led By Otis Owens, PhD

Research Sponsored by University of South Carolina

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be a White or African-American survivor of NSCLC, stages I-III

Timeline

Screening 3 weeks

Treatment Varies

Follow Up administered prior to the start of intervention and immediately following the intervention.

Awards & highlights

No Placebo-Only Group

Summary

This trial evaluates if an app helps lung cancer survivors manage their symptoms and improve their quality of life.

Who is the study for?

This trial is for White or African-American survivors of non-small cell lung cancer (NSCLC) stages I-III. Participants must have a smartphone, internet access, and be willing to use a mobile app for daily meditations and gentle exercises over 8 weeks.

What is being tested?

The 'Breathe Easier' progressive web application is being tested to see if it can help lung cancer survivors manage symptoms like shortness of breath and fatigue, and improve their quality of life. The study will compare users of the app with those who do not receive any intervention.

What are the potential side effects?

Since this intervention involves mindfulness practices through an app, there are no direct medical side effects expected from its use. However, participants may experience varying levels of engagement or satisfaction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a White or African-American survivor of early-stage lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ administered only to intervention group immediately following the 8-week intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~administered only to intervention group immediately following the 8-week intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and administered only to intervention group immediately following the 8-week intervention for reporting.